Zentalis Pharmaceuticals, Inc.
ZNTLNASDAQHealthcareBiotechnology
As of Oct 26, 2026 close
- Market cap
- $147.64M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $1.21$6.95
- Volume (live)
- -
- Avg. volume (3M)
- 1.35M
Zentalis Pharmaceuticals (ZNTL) Stock Price & Financial Analysis
Zentalis Pharmaceuticals Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $2.03 - $2.27 |
|---|---|
| 52-Week High | $6.95 |
| 52-Week Low | $1.21 |
| Open | $2.21 |
| Volume (last close) | 1.06M |
| Average Volume (3M) | 1.35M |
| 50-Day MA | $3.23 |
|---|---|
| 200-Day MA | $3.48 |
| 1-Year Change | +46.95% |
| Market Cap | 147.64M |
|---|---|
| Shares Outstanding | 71.33M |
| Price to Book (P/B) | 1.03 |
| EV/EBITDA | -1.23 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
Source: Market prices and company fundamentals. Data as of Oct 26, 2026. Data sources and methodology
Zentalis Pharmaceuticals at a Glance
As of the Oct 26, 2026 close, Zentalis Pharmaceuticals (ZNTL) has a market capitalization of $147.64M. Revenue fell 100.0% year over year.
As of its latest reported balance sheet, it holds $24.78M in cash and securities against $37.69M of debt, a net debt position of $12.91M.
Zentalis Pharmaceuticals does not currently pay a dividend.
The share price is up 47.0% over the past year. At $2.07 (the Oct 26, 2026 close) it sits near the bottom of its 52-week range of $1.21 to $6.95, below its 200-day moving average of $3.48.
Based on 8 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $7.67, 270.5% above the Oct 26, 2026 close.
Frequently Asked Questions About Zentalis Pharmaceuticals
What is the current stock price for ZNTL?
As of the Oct 26, 2026 close, ZNTL stock trades at $2.07. The 52-week range is $1.21–$6.95, with a day range of $2.03–$2.27.
What is the P/E ratio for ZNTL?
The P/E ratio (Price-to-Earnings) for ZNTL is shown in the Key Statistics section. This valuation metric helps compare Zentalis Pharmaceuticals, Inc. to industry peers.
Does ZNTL pay dividends?
Zentalis Pharmaceuticals does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for ZNTL?
Based on ratings from 8 professional analysts over the last 90 days, the consensus for ZNTL is Buy. The average 12-month price target is $7.67, a 270.5% upside from the Oct 26, 2026 close of $2.07.
What is the market cap of ZNTL?
As of the Oct 26, 2026 close, Zentalis Pharmaceuticals's market capitalization is $147.6M, classifying it as a micro-cap company. Zentalis Pharmaceuticals operates in the Healthcare sector within the Biotechnology industry.